SCHEMBL3300939

SCHEMBL3300939

FC(F)(F)c1cc(NC(=S)NCc2ccc(Cl)cc2)cc(C(F)(F)F)c1

nearest known ligand 0.79

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.79
MEN1 O00255 9/20 0.79
KMT2A Q03164 9/20 0.79
NPSR1 Q6W5P4 3/20 0.79
HTT P42858 2/20 0.79
MYC P01106 1/20 0.75
MAX P61244 1/20 0.75
GAA P10253 4/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
HPGD P15428 4/20 0.61
ALOX12 P18054 2/20 0.61
ALDH1A1 P00352 7/20 0.61
LMNA P02545 6/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
CYP19A1 P11511 1/20 0.56
MAPK1 P28482 1/20 0.53
MAOA P21397 1/20 0.53
MAOB P27338 1/20 0.53
BLM P54132 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3298774 0.87 ALDH1A1 (0.78) MAPTMEN1KMT2ANPSR1HTT
SCHEMBL3297435 0.86 MAPT (0.64) MAPTMEN1KMT2ANPSR1HTT
SCHEMBL3302805 0.86 MYC (0.67) MAPTMEN1KMT2ANPSR1HTT
SCHEMBL3300219 0.86 MYC (0.75) MAPTMEN1KMT2ANPSR1HTT
SCHEMBL3299625 0.86 MYC (1.00) MAPTMEN1KMT2ANPSR1HTT
SCHEMBL3305997 0.85 MYC (0.74) MAPTMEN1KMT2ANPSR1HTT
SCHEMBL3301650 0.83 MAPT (0.66) MAPTMEN1KMT2ANPSR1HTT
SCHEMBL3297371 0.83 MYC (0.70) MAPTMEN1KMT2ANPSR1HTT
SCHEMBL4555022 0.82 MAPT (0.67) MAPTMEN1KMT2ANPSR1HTT
SCHEMBL24742588 0.82 MYC (0.68) MAPTMEN1KMT2ANPSR1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093864-A1 ANTI-INFECTIVE THIOUREA COMPOUNDS LICA PHARMACEUTICALS (DK) 2010-04-15 US claimed
EP-2074085-A2 ANTI-INFECTIVE THIOUREA COMPOUNDS Lica Pharmaceuticals A/S (DK) 2009-07-01 EP claimed
WO-2008043840-A2 ANTI-INFECTIVE THIOUREA COMPOUNDS LICA PHARMACEUTICALS (DK) 2008-04-17 WO claimed
US-20100093864-A1 ANTI-INFECTIVE THIOUREA COMPOUNDS LICA PHARMACEUTICALS (DK) 2010-04-15 US disclosed
EP-2074085-A2 ANTI-INFECTIVE THIOUREA COMPOUNDS Lica Pharmaceuticals A/S (DK) 2009-07-01 EP disclosed
WO-2008043840-A2 ANTI-INFECTIVE THIOUREA COMPOUNDS LICA PHARMACEUTICALS (DK) 2008-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093864-A1 ANTI-INFECTIVE THIOUREA COMPOUNDS TST, TPX2, TPMT MAPT 4691/4885MEN1 3755/4885KMT2A 1919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.